The Freemasons Foundation Centre for Men’s Health’s Associate Professor Lisa Butler , now based in the Cancer Theme at the South Australian Health and Medical Research Institute (SAHMRI), and colleagues have been awarded a prestigious $3.25 million Revolutionary Team Award from the Movember Foundation and the Prostate Cancer Foundation of Australia (PCFA).
The Revolutionary Team comprises leading scientists and clinicians in the field of prostate cancer, lipids, obesity, imaging and biostatistics across Australia and Belgium and includes:
- Associate Professor Lisa Butler (Team Leader) and Dr Margaret Centenera from the Uni of Adelaide’s Prostate Cancer Research Group, SAHMRI – Freemasons Foundation Centre for Men’s Health
- Professor Wayne Tilley and Dr Luke Selth from the Uni of Adelaide’s Adelaide Prostate Cancer Research Centre, Dame Roma Mitchell Cancer Research Laboratories, Freemasons Foundation Centre for Men’s Health
- Professor Gary Wittert, and Dr Andrew Vincent; University of Adelaide, Freemasons Foundation Centre for Men’s Health
- Professor Andrew Scott, The Ludwig Institute for Cancer Research in Melbourne
- Dr Andrew Hoy, the University of Sydney
- Professor Johannes Swinnen, the University of Leuven, Belgium, and many more.
The project will address one of the most urgent needs in prostate cancer management – the ability to distinguish, at the time of diagnosis, between patients with significant life-threatening cancer, and those with organ-confined cancer that may not need to be treated at all. The three-year project will focus on lipids in prostate tumours as a completely new way of predicting the cancer’s future behaviour. The aim is to identify a specific signature of lipids that can be readily detected in the tumour tissue, using state-of-the-art imaging, to help determine which tumours are more likely to spread aggressively through the body.
The project brings together the Centre’s expertise in male obesity and prostate cancer. There is a link between obesity and the incidence of prostate cancer and we already know that obesity influences lipid metabolism in prostate cancer. This project will also help to better understand the role of altered lipid metabolism and prostate cancer biology and disease progression, the role of exogenous fatty acids (dietary and from fat stores), and therefore the potential modifying role of obesity in disease and treatment.
Much of the research that informed the development of this project was also funded by the PCFA highlighting the invaluable role that the PCFA and Movember continue to play in supporting advances in prostate cancer prevention and treatment and improving men’s health.